Pharmaceutical Technology

JUNE 6, 2025

The approval process for cell and gene therapy candidates is tricky, however, given their high-cost and oft-debated benefit-risk ratio. RFK Jr did not question their importance, and acknowledged panellists’ calls for faster regulatory processes. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Insurance Coverage and Processing 81

Insurance Coverage and Processing Communication Hospitals Drug Development 81

Putting Patients First Blog

JULY 2, 2024

General Comments The NHC appreciates CMS’ commitment to actively engaging with stakeholders, including patients, consumer advocates, and health experts, in implementing the Medicare Drug Price Negotiation Program (DPNP). The NHC provides the following comments to CMS to improve on the steps it has already taken to date.

Drug Pricing 52

Drug Pricing Insurance Coverage and Processing Labelling HIPAA 52

Putting Patients First Blog

JANUARY 27, 2025

Coverage of Anti-Obesity Medications (AOMs) The NHC applauds CMS for aligning with the medical community and proposing to recognize obesity as a chronic disease and allow Medicare Part D coverage for AOMs. Below, we provide detailed comments and recommendations on key provisions of the proposed rule.

Insurance Coverage and Processing 40

Insurance Coverage and Processing Biosimilars Communication Department of Veterans Affairs 40

Pharmaceutical Commerce

JUNE 17, 2025

Intelligent medication management systems using RWD help hospitals forecast demand, respond to crises, and minimize medication expiration and loss, ultimately improving patient care and operational efficiency. The FDA oversees over 23,000 prescription drug products approved for marketing in the US 1 and ultimately, an estimated 361.3

52

52

Proxsys Rx

AUGUST 16, 2023

“Don’t believe drug companies: 340B is a program worth saving” On Tuesday, August 8, The Hill published a guest editorial (title above) by John Hassell — national director of advocacy at the AIDS Healthcare Foundation (AHF). First, start with presenting drug company-funded research as if it is non-biased. drug market.

Insurance Coverage and Processing 52

Insurance Coverage and Processing Hospitals Drug Pricing Pharmaceutical Companies 52

Pharmaceutical Technology

JUNE 10, 2025

Go deeper with GlobalData Reports United States of America (USA) Drug Pricing and Reimbursement Lands. Nominate Now Share Copy Link Share on X Share on Linkedin Share on Facebook Go deeper with GlobalData Reports United States of America (USA) Drug Pricing and Reimbursement Lands.

Vaccines 52

Vaccines Insurance Coverage and Processing Drug Pricing Immunization 52

Pharmacy Times

JUNE 16, 2025

According to Trump, patients could see cost reductions of 30% to 80%, but experts question the feasibility and practicality of implementing such a policy within the complex United States drug pricing and supply system.

Pharmacy Technician 26

Pharmacy Technician Drug Pricing Insurance Coverage and Processing Compounding Pharmacies 26